Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotrovimab PK and Safety Study
NCT05280717Phase 1Terminated
- Sponsor
- Vir Biotechnology
- Start
- Mar 2022
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sotrovimab in coronavirus disease 2019 (COVID-19) (7 arms), sponsored by Vir Biotechnology. Primary endpoints: Area Under the Serum Concentration-time Curve From Day 1 to Day 29, Maximum Observed Concentration at Day 29 and 1 more. Started Mar 2022; status: terminated.
02
Drugs
sotrovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05280717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05280717.